Nuvectra (NVTR) Getting Positive News Coverage, Study Finds

Press coverage about Nuvectra (NASDAQ:NVTR) has been trending positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nuvectra earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.7160626353623 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Nuvectra (NASDAQ:NVTR) opened at $8.46 on Wednesday. Nuvectra has a twelve month low of $4.90 and a twelve month high of $15.00. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.90 and a quick ratio of 2.72.

Nuvectra (NASDAQ:NVTR) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($1.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.07. The firm had revenue of $7.60 million during the quarter, compared to analysts’ expectations of $8.08 million. Nuvectra had a negative return on equity of 68.63% and a negative net margin of 204.19%. The company’s quarterly revenue was up 100.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.92) EPS. research analysts anticipate that Nuvectra will post -4.58 earnings per share for the current fiscal year.

Several brokerages have weighed in on NVTR. ValuEngine cut Nuvectra from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Piper Jaffray Companies reissued a “hold” rating and set a $12.00 price objective on shares of Nuvectra in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $12.00.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at

Nuvectra Company Profile

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Insider Buying and Selling by Quarter for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply